This company listing is no longer active
V9Z Stock Overview
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aceragen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.24 |
| 52 Week High | €11.09 |
| 52 Week Low | €0.24 |
| Beta | 1.2 |
| 11 Month Change | -64.96% |
| 3 Month Change | -84.00% |
| 1 Year Change | -97.16% |
| 33 Year Change | -99.14% |
| 5 Year Change | -99.82% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| V9Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.6% | -1.9% | -0.6% |
| 1Y | -97.2% | -18.1% | 9.6% |
Return vs Industry: V9Z underperformed the German Biotechs industry which returned -5.5% over the past year.
Return vs Market: V9Z underperformed the German Market which returned 10.9% over the past year.
Price Volatility
| V9Z volatility | |
|---|---|
| V9Z Average Weekly Movement | 30.6% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V9Z's share price has been volatile over the past 3 months.
Volatility Over Time: V9Z's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia.
Aceragen, Inc. Fundamentals Summary
| V9Z fundamental statistics | |
|---|---|
| Market cap | €2.02m |
| Earnings (TTM) | -€38.03m |
| Revenue (TTM) | €6.79m |
0.3x
P/S Ratio-0.1x
P/E RatioIs V9Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V9Z income statement (TTM) | |
|---|---|
| Revenue | US$7.33m |
| Cost of Revenue | US$15.40m |
| Gross Profit | -US$8.06m |
| Other Expenses | US$32.98m |
| Earnings | -US$41.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.88 |
| Gross Margin | -110.00% |
| Net Profit Margin | -559.86% |
| Debt/Equity Ratio | 1.3% |
How did V9Z perform over the long term?
See historical performance and comparison